Home › Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimers Disease
 

Keywords :   


Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimers Disease

2013-07-14 14:30:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. Merck, known as MSD outside the United States and Canada, today announced the presentation of results from a Phase Ib study showing a dose-dependent decrease in amyloid levels in cerebral spinal fluid (CSF) following administration of MK-8931, Mercks investigational oral -site amyloid precursor protein cleaving enzyme (BACE1 or secretase) inhibitor, in patients with mild to moderate Alzheimers disease (AD). In the study, amyloid levels were analyzed as a measure of BACE activity. Language:  English Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: with study phase disease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Still no sign of herd rebuilding
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
More »